Temaril-P® Spansule Capsule No. 1 - Share Your Temaril-P® Spansule Capsule No. 1 Experience with Community:
blog comments powered by DisqusNADA Number: 035-161 | |
| Proprietary Name |
Temaril-P® Spansule Capsule No. 1 Temaril-P® Spansule Capsule No. 2 |
|---|---|
| Sponsor |
Pfizer, Inc. |
| Sponsor Address |
235 East 42d St. New York, NY 10017 USA |
| Ingredients |
Prednisolone Trimeprazine Tartrate |
| Species |
Dog, restricted during pregnancy |
| Routes of Administration |
Per Os |
| Dose Form |
Capsule |
| Drug Form |
Capsule |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.2605 Trimeprazine tartrate and prednisolone capsules. Specifications: Each capsule contains 3.75 milligrams of trimeprazine in sustained released form (as the tartrate) and 1 milligram of prednisolone (capsule no. 1) or 7.5 milligrams of trimeprazine in sustained release form (as the tartrate) and 2 milligrams of prednisolone (capsule no. 2). Conditions of use: Dogs Amount: Up to 10 pounds body weight- 1 #1 capsule orally once daily 11 to 20 pounds body weight- 2 #1 capsules or 1 #2 capsule orally once daily 21 to 40 pounds body weight- 4 #1 capsules or 2 #2 capsules orally once daily Over 40 pounds body weight- 6 #1 capsules or 3 #2 capsules orally once daily Indications: For the relief of itching regardless of cause reduction of inflammation commonly associated with most skin disorders of dogs such as eczema caused by internal disorders, otitis, and dermatitis (allergic, parasitic, pustular and nonspecific). It is also used in dogs as adjunctive therapy in various cough conditions including treatment of "kennel cough" or tracheobronchitis, bronchitis including allergic bronchitis, tonsillitis, acute upper respiratory infections, and coughs of nonspecific origin. The product may also be administered to dogs suffering from acute or chronic bacterial infections, provided the infection is controlled by appropriate antibiotic or chemotherapeutic agents. Limitations: After 4 days, reduce dosage to one-half the initial dose or to an amount sufficient to maintain remission of symptoms. Dosages in individual cases may vary and should be adjusted until proper response is obtained. Do not use the drug in cases of viral infections involving corneal ulceration or dendritic ulceration of the cornea. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. |
| Tolerances |
A tolerance of zero is established for residues of prednisolone in milk from dairy animals. |